Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial
© 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2020
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/51415 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.51415 |
---|---|
record_format |
dspace |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Walter R.J. Taylor Kamala Thriemer Lorenz von Seidlein Prayoon Yuentrakul Thanawat Assawariyathipat Ashenafi Assefa Sarah Auburn Krisin Chand Nguyen Hoang Chau Phaik Yeong Cheah Le Thanh Dong Mehul Dhorda Tamiru Shibru Degaga Angela Devine Lenny L. Ekawati Fahmi Fahmi Asrat Hailu Mohammad Anwar Hasanzai Tran Tinh Hien Htee Khu Benedikt Ley Yoel Lubell Jutta Marfurt Hussein Mohammad Kerryn A. Moore Mohammad Nader Naddim Ayodhia Pitaloka Pasaribu Syahril Pasaribu Cholrawee Promnarate Awab Ghulam Rahim Pasathron Sirithiranont Hiwot Solomon Herawati Sudoyo Inge Sutanto Ngo Viet Thanh Nguyen Thi Tuyet-Trinh Naomi Waithira Adugna Woyessa Fazal Yamin Yamin Arjen Dondorp Julie A. Simpson J. Kevin Baird Nicholas J. White Nicholas P. Day Ric N. Price Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial |
description |
© 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vivax malaria. Methods: We did a randomised, double-blind, placebo-controlled, non-inferiority trial in eight health-care clinics (two each in Afghanistan, Ethiopia, Indonesia, and Vietnam). Patients (aged ≥6 months) with normal glucose-6-phosphate dehydrogenase (G6PD) and presenting with uncomplicated vivax malaria were enrolled. Patients were given standard blood schizontocidal treatment and randomly assigned (2:2:1) to receive 7 days of supervised primaquine (1·0 mg/kg per day), 14 days of supervised primaquine (0·5 mg/kg per day), or placebo. The primary endpoint was the incidence rate of symptomatic P vivax parasitaemia during the 12-month follow-up period, assessed in the intention-to-treat population. A margin of 0·07 recurrences per person-year was used to establish non-inferiority of the 7-day regimen compared with the 14-day regimen. This trial is registered at ClinicalTrials.gov (NCT01814683). Findings: Between July 20, 2014, and Nov 25, 2017, 2336 patients were enrolled. The incidence rate of symptomatic recurrent P vivax malaria was 0·18 (95% CI 0·15 to 0·21) recurrences per person-year for 935 patients in the 7-day primaquine group and 0·16 (0·13 to 0·18) for 937 patients in the 14-day primaquine group, a difference of 0·02 (−0·02 to 0·05, p=0·3405). The incidence rate for 464 patients in the placebo group was 0·96 (95% CI 0·83 to 1·08) recurrences per person-year. Potentially drug-related serious adverse events within 42 days of starting treatment were reported in nine (1·0%) of 935 patients in the 7-day group, one (0·1%) of 937 in the 14-day group and none of 464 in the control arm. Four of the serious adverse events were significant haemolysis (three in the 7-day group and one in the 14-day group). Interpretation: In patients with normal G6PD, 7-day primaquine was well tolerated and non-inferior to 14-day primaquine. The short-course regimen might improve adherence and therefore the effectiveness of primaquine for radical cure of P vivax malaria. Funding: UK Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme (MR/K007424/1) and the Bill & Melinda Gates Foundation (OPP1054404). |
author2 |
Melbourne School of Population and Global Health |
author_facet |
Melbourne School of Population and Global Health Walter R.J. Taylor Kamala Thriemer Lorenz von Seidlein Prayoon Yuentrakul Thanawat Assawariyathipat Ashenafi Assefa Sarah Auburn Krisin Chand Nguyen Hoang Chau Phaik Yeong Cheah Le Thanh Dong Mehul Dhorda Tamiru Shibru Degaga Angela Devine Lenny L. Ekawati Fahmi Fahmi Asrat Hailu Mohammad Anwar Hasanzai Tran Tinh Hien Htee Khu Benedikt Ley Yoel Lubell Jutta Marfurt Hussein Mohammad Kerryn A. Moore Mohammad Nader Naddim Ayodhia Pitaloka Pasaribu Syahril Pasaribu Cholrawee Promnarate Awab Ghulam Rahim Pasathron Sirithiranont Hiwot Solomon Herawati Sudoyo Inge Sutanto Ngo Viet Thanh Nguyen Thi Tuyet-Trinh Naomi Waithira Adugna Woyessa Fazal Yamin Yamin Arjen Dondorp Julie A. Simpson J. Kevin Baird Nicholas J. White Nicholas P. Day Ric N. Price |
format |
Article |
author |
Walter R.J. Taylor Kamala Thriemer Lorenz von Seidlein Prayoon Yuentrakul Thanawat Assawariyathipat Ashenafi Assefa Sarah Auburn Krisin Chand Nguyen Hoang Chau Phaik Yeong Cheah Le Thanh Dong Mehul Dhorda Tamiru Shibru Degaga Angela Devine Lenny L. Ekawati Fahmi Fahmi Asrat Hailu Mohammad Anwar Hasanzai Tran Tinh Hien Htee Khu Benedikt Ley Yoel Lubell Jutta Marfurt Hussein Mohammad Kerryn A. Moore Mohammad Nader Naddim Ayodhia Pitaloka Pasaribu Syahril Pasaribu Cholrawee Promnarate Awab Ghulam Rahim Pasathron Sirithiranont Hiwot Solomon Herawati Sudoyo Inge Sutanto Ngo Viet Thanh Nguyen Thi Tuyet-Trinh Naomi Waithira Adugna Woyessa Fazal Yamin Yamin Arjen Dondorp Julie A. Simpson J. Kevin Baird Nicholas J. White Nicholas P. Day Ric N. Price |
author_sort |
Walter R.J. Taylor |
title |
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial |
title_short |
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial |
title_full |
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial |
title_fullStr |
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial |
title_full_unstemmed |
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial |
title_sort |
short-course primaquine for the radical cure of plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial |
publishDate |
2020 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/51415 |
_version_ |
1763487577891930112 |
spelling |
th-mahidol.514152020-01-27T16:30:33Z Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial Walter R.J. Taylor Kamala Thriemer Lorenz von Seidlein Prayoon Yuentrakul Thanawat Assawariyathipat Ashenafi Assefa Sarah Auburn Krisin Chand Nguyen Hoang Chau Phaik Yeong Cheah Le Thanh Dong Mehul Dhorda Tamiru Shibru Degaga Angela Devine Lenny L. Ekawati Fahmi Fahmi Asrat Hailu Mohammad Anwar Hasanzai Tran Tinh Hien Htee Khu Benedikt Ley Yoel Lubell Jutta Marfurt Hussein Mohammad Kerryn A. Moore Mohammad Nader Naddim Ayodhia Pitaloka Pasaribu Syahril Pasaribu Cholrawee Promnarate Awab Ghulam Rahim Pasathron Sirithiranont Hiwot Solomon Herawati Sudoyo Inge Sutanto Ngo Viet Thanh Nguyen Thi Tuyet-Trinh Naomi Waithira Adugna Woyessa Fazal Yamin Yamin Arjen Dondorp Julie A. Simpson J. Kevin Baird Nicholas J. White Nicholas P. Day Ric N. Price Melbourne School of Population and Global Health Arba Minch University Federal Ministry of Health - Ethiopia Addis Ababa University Universitas Sumatera Utara Eijkman Institute for Molecular Biology Universitas Indonesia Menzies School of Health Research UCL Mahidol University Nuffield Department of Clinical Medicine Burnet Institute Krong-Pa Health Centre Ethiopian Public Health Institute Nangarhar University Eijkman Institute of Molecular Biology Health Protection and Research Organisation Health and Social Development Organization Institute of Malariology, Parasitology and Entomology Medicine © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vivax malaria. Methods: We did a randomised, double-blind, placebo-controlled, non-inferiority trial in eight health-care clinics (two each in Afghanistan, Ethiopia, Indonesia, and Vietnam). Patients (aged ≥6 months) with normal glucose-6-phosphate dehydrogenase (G6PD) and presenting with uncomplicated vivax malaria were enrolled. Patients were given standard blood schizontocidal treatment and randomly assigned (2:2:1) to receive 7 days of supervised primaquine (1·0 mg/kg per day), 14 days of supervised primaquine (0·5 mg/kg per day), or placebo. The primary endpoint was the incidence rate of symptomatic P vivax parasitaemia during the 12-month follow-up period, assessed in the intention-to-treat population. A margin of 0·07 recurrences per person-year was used to establish non-inferiority of the 7-day regimen compared with the 14-day regimen. This trial is registered at ClinicalTrials.gov (NCT01814683). Findings: Between July 20, 2014, and Nov 25, 2017, 2336 patients were enrolled. The incidence rate of symptomatic recurrent P vivax malaria was 0·18 (95% CI 0·15 to 0·21) recurrences per person-year for 935 patients in the 7-day primaquine group and 0·16 (0·13 to 0·18) for 937 patients in the 14-day primaquine group, a difference of 0·02 (−0·02 to 0·05, p=0·3405). The incidence rate for 464 patients in the placebo group was 0·96 (95% CI 0·83 to 1·08) recurrences per person-year. Potentially drug-related serious adverse events within 42 days of starting treatment were reported in nine (1·0%) of 935 patients in the 7-day group, one (0·1%) of 937 in the 14-day group and none of 464 in the control arm. Four of the serious adverse events were significant haemolysis (three in the 7-day group and one in the 14-day group). Interpretation: In patients with normal G6PD, 7-day primaquine was well tolerated and non-inferior to 14-day primaquine. The short-course regimen might improve adherence and therefore the effectiveness of primaquine for radical cure of P vivax malaria. Funding: UK Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme (MR/K007424/1) and the Bill & Melinda Gates Foundation (OPP1054404). 2020-01-27T09:30:33Z 2020-01-27T09:30:33Z 2019-09-14 Article The Lancet. Vol.394, No.10202 (2019), 929-938 10.1016/S0140-6736(19)31285-1 1474547X 01406736 2-s2.0-85071980923 https://repository.li.mahidol.ac.th/handle/123456789/51415 Mahidol University SCOPUS https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071980923&origin=inward |